KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) was the target of a large decline in short interest in August. As of August 15th, there was short interest totalling 5,680,000 shares, a decline of 5.0% from the July 31st total of 5,980,000 shares. Based on an average trading volume of 317,000 shares, the short-interest ratio is currently 17.9 days.

KalVista Pharmaceuticals Trading Up 3.0 %

Shares of NASDAQ KALV opened at $13.39 on Tuesday. KalVista Pharmaceuticals has a 1-year low of $7.21 and a 1-year high of $16.88. The company has a 50-day moving average of $13.09 and a two-hundred day moving average of $12.45. The company has a market cap of $576.84 million, a PE ratio of -3.94 and a beta of 0.91.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.29). As a group, equities research analysts forecast that KalVista Pharmaceuticals will post -3.57 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on KALV. Needham & Company LLC decreased their price objective on shares of KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, July 15th. Finally, Cantor Fitzgerald upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 26th.

Insider Activity

In related news, CEO Benjamin L. Palleiko sold 7,465 shares of the stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $11.53, for a total value of $86,071.45. Following the completion of the transaction, the chief executive officer now owns 224,547 shares of the company’s stock, valued at $2,589,026.91. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,135 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $12.40, for a total transaction of $26,474.00. Following the completion of the transaction, the insider now directly owns 83,745 shares of the company’s stock, valued at $1,038,438. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,465 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $11.53, for a total transaction of $86,071.45. Following the completion of the sale, the chief executive officer now directly owns 224,547 shares in the company, valued at approximately $2,589,026.91. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,917 shares of company stock worth $368,563. Corporate insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in KalVista Pharmaceuticals in the second quarter valued at approximately $25,000. AJOVista LLC acquired a new stake in shares of KalVista Pharmaceuticals during the fourth quarter worth $60,000. EntryPoint Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals during the first quarter worth $92,000. China Universal Asset Management Co. Ltd. increased its holdings in KalVista Pharmaceuticals by 101.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after purchasing an additional 4,043 shares during the last quarter. Finally, Entropy Technologies LP acquired a new position in KalVista Pharmaceuticals in the first quarter valued at about $121,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.